Effects of Thiazolidinediones on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After Drug-Eluting Stent Implantation: A Retrospective Cohort Study Using the National Health Insurance Database in Taiwan

Clinical Therapeutics

Volumn 34, Issue 4, 2012, Pages 885-893

  Yeh, Hsien Tsung ^a   Hsieh, Chi Feng ^a   Tsai, Yi Wen ^a   Huang, Weng Foung ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular events; Clinical Outcomes; Diabetic Patients; Drug Eluting Stent (DES); Thiazolidinediones

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; PACLITAXEL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DEATH; DRUG EFFECT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NATIONAL HEALTH INSURANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; REPEAT PROCEDURE; RETROSPECTIVE STUDY; TAIWAN; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; RETROSPECTIVE STUDIES; STENTS; TAIWAN; THIAZOLIDINEDIONES;

EID: 84859588797     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.024     Document Type: Article

References (33)

1. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004, 350:221-231.
2. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
3. Mauri L., Hsieh W., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007, 356:1020-1029.
4. Cutlip D.E., Baim D.S., Ho K.K., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001, 103:1967-1971.
5. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126-2130.
6. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006, 113:1108-1113.
7. Urban P., Gershlick A.H., Guagliumi G., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006, 113:1434-1441.
8. Frobert O., Lagerqvist B., Carlsson J., et al. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009, 53:1660-1667.
9. Billinger M., Beutler J., Taghetchian K.R., et al. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J 2008, 29:718-725.
10. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
11. Hsueh W.A., Jackson S., Law R.E. Control of vascular cell proliferation and migration by PPAR-γ: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001, 24:392-397.
12. Schoonjans K., Auwerx J. Thiazolidinediones: an update. Lancet 2000, 355:1008-1010.
13. Geng D.F., Jin D.M., Wu W., et al. Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials. Atherosclerosis 2009, 202:521-528.
14. Rosmarakis E.S., Falagas M.E. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J 2007, 154:144-150.
15. Takagi T., Okura H., Kobayashi Y., et al. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). J Am Coll Cardiol Intv 2009, 2:524-531.
16. Nishio K., Shigemitsu M., Kodama Y., et al. Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with type 2 diabetes mellitus. Cardiovasc Revasc Med 2009, 10:5-11.
17. Schomig A., Kastrati A., Wessely R. Prevention of restenosis by systemic drug therapy: back to the future?. Circulation 2005, 112:2759-2761.
18. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115. 2344-2251.
19. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
20. Singh S., Loke Y.K., Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189-1195.
21. Kitahara H., Kobayashi Y., Iwata Y., et al. Effect of pioglitazone on endothelial dysfunction after sirolimus-eluting stent implantation. Am J Cardiol 2011, 108:214-219.
22. Ozawa T., Oda H., Oda M., et al. Improved cardiac function after sirolimus-eluting stent placement in diabetic patients by pioglitazone: combination therapy with statin. J Cardiol 2009, 53:402-409.
23. Kastrati A., Schomig A., Dietz R., et al. Time course of restenosis during the first year after emergency coronary stenting. Circulation 1993, 87:1498-1505.
24. National Health Insurance Research Database, Taiwan, Accessed August 9, 2011. http://w3.nhri.org.tw/nhird/en/index.htm.
25. Klein J.P., Moeschberger M.L. Survival Analysis 2003, Springer, New York. 2nd Ed.
26. Romano P.S., Roos L.L., Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993, 46:1075-1079.
27. Marx N., Wohrle J., Nusser T., et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005, 112:2792-2798.
28. Katayama T., Ueba H., Tsuboi K., et al. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. Am Heart J 2007, 153:762.e1-762.e7.
29. Riche D.M., Valderrama R., Henyan N.N. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care 2007, 30:384-388.
30. Park D.W., Park S.W., Park K.H., et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006, 98:352-356.
31. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007, 115:2435-2441.
32. Finn A.V., John M., Nakazawa G., et al. Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor γ agonists: requirement for mTOR/Akt2 in PPAR-γ activation. Circ Res 2009, 105:1003-1012.
33. Hsiao A., Worrall D.S., Olefsky J.M., et al. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 2004, 20:3108-3127.